Compare Citius Pharmaceuticals Inc (CTXR) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs T-Mobile Us Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while T-Mobile Us Inc trades at $148.58 (market cap $183.76B). The key difference: T-Mobile Us Inc is far larger — about 13491.9× Citius Pharmaceuticals Inc's market cap, and T-Mobile Us Inc pays a 2.73% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and T-Mobile Us Inc for 84 Days on average.
| CTXR | TMUS | |
|---|---|---|
Market Cap | $13.62M | $183.76B |
Volume | 132,438 | 4,294,650 |
Sector | Health | Media |
52-Week High | $1.82 | $230.06 |
52-Week Low | $0.48 | $161.73 |
Typical Hold Time | 17 Days | 84 Days |
Enterprise Value | $3.79M | $300.37B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4994, down 1.73% with a bearish technical signal despite oscillators showing oversold conditions. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR commercial sales, but continues to post significant losses with a -651.27% net income margin. Recent news highlights strong commercial momentum for LYMPHIR with 44 institutions ordering the treatment since launch.
The stock presents a high-risk opportunity with analyst consensus strongly bullish (83% buy ratings, $5 price target) but fundamental challenges persist. Key risks include ongoing cash burn and execution of commercial strategy, while potential upside depends on successful LYMPHIR adoption and path to profitability.
TMUS trades at $171.31, up 2.2% today, with a bullish technical signal and strong analyst support. Recent earnings beat expectations in Q1 and Q2 2026, with revenue growth to $88.31B in 2025. The company announced a 15% dividend hike and is advancing AI-driven 5G network upgrades, while maintaining robust profitability with a net margin of 11.45%.
Outlook remains positive given earnings momentum and strategic initiatives, but risks include high debt levels and competitive pressures. The consensus price target of $231.10 implies significant upside, supported by 79.6% buy ratings from analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
